Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-05-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Gencurix Inc.' (젠큐릭스) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, capital structure, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location (online), target audience, and the purpose of the meeting. It does not contain the actual presentation slides or financial data, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) if it does not fit into more specific categories like RPA (which is typically for report publication). Since this is a notice of an IR event, RNS is the most appropriate classification.
2023-05-12 Korean
[기재정정]기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Change in Management/Other Business Matters' (기타 경영사항). Specifically, it details the conversion of convertible preferred shares into common shares, which results in a change in the company's capital structure and share count. Since this involves the issuance of new shares through conversion, it falls under the category of share capital changes.
2023-05-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders (specifically Cho Sang-rae and related parties) due to capital changes like paid-in capital increases (유상증자). This type of filing is categorized as a Major Shareholding Notification (MRQ) as it tracks significant ownership thresholds and changes in equity stakes.
2023-04-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific individual (Han Jinil) at Gencurix. This is a standard regulatory filing for insider trading or director/executive shareholding changes, which corresponds to the 'Director's Dealing' category.
2023-04-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of a specific individual (Cho Sang-rae, CEO of Gencurix) due to a capital increase. This type of filing is a standard regulatory requirement for insider trading or changes in ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2023-04-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.